NCT04113863 - Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

June 18, 2019

Primary Completion Date

August 31, 2024

Study Completion Date

September 30, 2024

Conditions

Breast Neoplasm Female

Interventions

DRUG

all-trans retinoic acid

Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days

DRUG

Anastrozole 1mg

Anastrozole will be administered orally at the dosage of 1 mg/die.

Trial Locations (2)

RECRUITING

ASST Papa Giovanni XXIII, Bergamo

RECRUITING

Ospedale Santa Maria della Misericordia di Udine, Udine

All Listed Sponsors

lead

Mario Negri Institute for Pharmacological Research

OTHER